Crohn's Disease Market
DelveInsight’s ‘Crohn’s Disease - Market Insights, Epidemiology, and Market Forecast–2032’ report delivers an in-depth understanding of the Crohn’s Disease historical and forecasted epidemiology as well as the Crohn’s Disease market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The Crohn’s Disease market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Crohn’s Disease market size. The Report also covers current Crohn’s Disease treatment practice, market drivers, market barriers, SWOT analysis, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Geography Covered
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan
Study Period: 2019–2032
Crohn’s Disease Understanding and Treatment
Crohn’s Disease Overview
CD is a type of Inflammatory Bowel Disease (IBD). It causes inflammation of the digestive tract, leading to abdominal pain, severe diarrhea, fatigue, weight loss, and malnutrition. Inflammation caused by CD can involve different areas of the digestive tract in different people. However, this type of IBD most commonly affects the small intestine and the start of the colon. CD can cause patches of inflammation that damage multiple layers of the GI tract wall. CD can be painful and sometimes may lead to life-threatening complications.
Crohn’s is sometimes described as a chronic condition. This means that it is ongoing and life-long. The disease runs a benign course with few flare-ups in many people, while other people may have more severe disease. CD is not infectious.
Continued in the report…..
Crohn’s Disease Diagnosis
Although the natural history of CD is well understood, diagnosis can be challenging, as it is not based on a single specific finding, and there are no pathognomonic features. Instead, diagnosis requires a complete assessment based on clinical history, physical examination, and complementary diagnostic tests, such as assays for serological and fecal biomarkers, cross-sectional and endoscopic imaging, and histological evaluation of biopsy specimens. There is no single test to confirm a Crohn’s diagnosis, and CD symptoms are often similar to other conditions, including bacterial infection.
Continued in the report…..
Crohn’s Disease Treatment
Management has two aims. First is treating the inflammatory process and its associated complications (e.g., abscesses, fistulas, strictures, intestinal obstructions) to achieve and maintain remission. The second is minimizing the negative health impacts of the CD itself and the therapies used to treat it. Historically, treatment of CD has relied mainly on corticosteroids and immunosuppressive medication with thiopurines (azathioprine [AZA]/5-mercaptopurin [5-MP]) or methotrexate (MTX).
Treatment decisions are guided by age, comorbidities, symptoms, inflammation status, disease location and extent, and overall risk of more severe and complicated disease. More severe disease and the presence of risk factors that predict poor prognosis justify the use of high-risk medications. Significant advancements have been made in treatment. Whereas, 5-aminosalicylates were once commonly used and are still prescribed for symptom management in mild-to-moderate disease, mucosal healing has not been demonstrated. Antibiotics, also widely used, should be limited to treating complications such as abscesses and fistulas. Medication management includes corticosteroids, immunomodulators, and biologics. Each plays a vital role in inducing or maintaining remission. Although no medicine cures CD, many can reduce symptoms.
Continued in the report…..
Crohn’s Disease Epidemiology
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Prevalent Cases of Crohn’s Disease, Diagnosed Prevalent Cases of Crohn’s Disease, Age-specific Diagnosed Prevalent Cases of Crohn’s Disease and Severity-specific Diagnosed Prevalent Cases of Crohn’s Disease scenario in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.
Key Findings
- Total prevalent population of Crohn's Disease in 7MM was estimated to be 1,613,413 cases in 2021, which is expected to increase by 2032.
- The US accounted for the highest prevalent population of Crohn’s Disease among 7MM with 832,145 cases in 2021.
- The estimates suggest a higher diagnosed prevalence of Crohn’s Disease in the United States with 595,304 diagnosed cases in 2021.
- Among the European countries, the total prevalent population of Crohn’s Disease was highest in Germany with 227,320 cases followed by the UK with 147,819 cases in 2021. Spain reported the least number of cases among EU-5 with 74,665 cases in 2021.
- Epidemiology assessed for Crohn’s Disease showed that Japan accounts for approximately 147,382 prevalent cases of CD in 2021.
- The estimates suggest in the United States, the age-specific diagnosed cases of Crohn’s disease (CD) were 353,611; 167,876; 67,865, and 5,953 cases for the age groups 18–44 years, 45–64 years, 65–84 years, and ≥85 years in 2021.
- As per DelveInsight’s analysis, the total cases of mild CD and moderate to severe CD were found to be 42,174 and 63,261 respectively in Japan in 2021.
Country-Wise Crohn’s Disease Epidemiology
The epidemiology segment also provides the Crohn’s Disease epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Crohn’s Disease Drug Chapters
Crohn’s Disease Marketed Drug
Entyvio (Vedolozumab): Takeda Pharmaceuticals
Entyvio (Vedolizumab) is a gut-selective biologic developed by Takeda Pharmaceutical and marketed under the trade name Entyvio. It is approved in the US for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) and Crohn’s disease (CD), who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor-alpha (TNFα)-antagonist. It is a humanized monoclonal antibody designed to specifically antagonize the alpha 4 beta 7 integrin, inhibiting the binding of alpha 4 beta 7 integrin to intestinal Mucosal Addressin Cell Adhesion Molecule 1 (MAdCAM-1), but not Vascular Cell Adhesion Molecule 1 (VCAM-1).
MAdCAM-1 is preferentially expressed on blood vessels and lymph nodes of the gastrointestinal tract. The alpha 4 beta 7 integrin is expressed on a subset of circulating white blood cells. These cells have been shown to play a role in mediating the inflammatory process in UC and CD. By inhibiting alpha 4 beta 7 integrin, vedolizumab may limit the ability of certain white blood cells to infiltrate gut tissues
Entyvio was approved by the for treatment of Ulcerative Colitis and Crohn’s Disease in 2014 whereas in 2020 the company announced that the US FDA has approved the company’s submission for its biologics manufacturing facility for the production of Entyvio (vedolizumab) drug substance.
Products detail in the report…
List to be continued in the report…
Crohn’s Disease Emerging Drugs
Jyselica (Filgotinib): Gilead Sciences/ Galapagos NV
Filgotinib is an orally bioavailable, investigational agent with potential anti-inflammatory and immunomodulating activities discovered and developed by Galapgos, in collaboration with Gilead. It is a selective JAK1 (Janus kinase 1) inhibitor. JAK1 is an enzyme with an essential role in the promotion of biologic responses induced by a subset of cytokine receptors, proteins that lead to inflammation. Upon oral administration, filgotinib specifically targets, binds to, and inhibits the phosphorylation of JAK1, which interferes with JAK/STAT (signal transducer and activator of transcription)-dependent signaling. Currently, Filgotinib is in the Phase III clinical development stage in the US for both the indications of Crohn's Disease and Ulcerative Colitis.
Products detail in the report…
Mirikizumab (LY3074828): Eilly Lilly and Company
Mirikizumab (LY3074828) is an investigational drug being developed by Eli Lilly and Company for the treatment of immune diseases, including Ulcerative Colitis and Crohn's Disease. It is a humanized IgG4 monoclonal antibody that binds to the P19 subunit of interleukin 23. LY3074828 (formerly known as IL-23 antibody) is a biologic entity that blocks the activity of the cytokine interleukin 23. Mirikizumab is being studied for the treatment of immune diseases, including psoriasis, ulcerative colitis and CD. Mirikizumab is currently in the Phase III developmental stage for the treatment of Crohn’s Disease and Ulcerative Colitis.
Products detail in the report…
List to be continued in the report…
Crohn’s Disease Market Outlook
Crohn’s disease (CD) is an inflammatory bowel disease (IBD) which are a group of disorders that cause chronic inflammation (pain and swelling) in the intestines. CD is progressive in nature with long-term damage to intestinal mucosal structures and recurrent attacks with acute exacerbations if not controlled and appropriately treated.
CD is often characterized by the formation of strictures, fistulas, ulcers, and granulomas in the mucosal layers of the intestine. It causes inflammation of the digestive tract lining, leading to abdominal pain, severe diarrhea, fatigue, weight loss, and malnutrition. However, the gastrointestinal manifestation associated with CD can primarily affect the terminal ileum and colon. Additionally, it can compromise any region from the mouth to the rectum of the affected patients.
Treatment effects and risk factors differ in different populations. The goal of medical treatment is to stop the abnormal inflammation so intestinal tissue has a chance to heal. As it does, the symptoms of diarrhea and abdominal pain should be relieved. Once the symptoms are under control, medical treatment will focus on decreasing the frequency of flare-ups and maintaining remission.
Treatment options for CD include nutritional therapy, smoking cessation, and pharmacological therapy, and in case of severe or chronic active disease, surgery is recommended. The goals of pharmacological therapy are to reduce symptoms and maintain/improve quality of life while decreasing the toxicity effects associated with drugs. Treatment typically begins with Glucocorticosteroids such as budesonide which is recommended as the first-line therapy, whereas; 5-aminosalicylate (5-ASA) is recommended in case glucocorticosteroids are contraindicated in the patients. As per the recommendation of the European Crohn’s and Colitis Organization (ECCO), in case of moderately active CD, azathioprine /6-mercaptopurine or methotrexate in combination with steroids are given to the patients. Glucocorticosteroids tend to provide rapid relief of symptoms along with a considerable decrease in inflammation. But because of side effects associated with their long-term use, corticosteroids are used only to treat flare-ups and are not used for maintaining remission.
The dynamics of the Crohn’s Disease market are anticipated to change during the forecasted period owing to the expected launch of emerging therapies during the forecasted period of 2022–2032.
Continued in the report…..
Key Findings
- The market size of Crohn’s Disease in the 7MM is estimated to be USD 7,801 million in 2021, which is further expected to increase by 2032.
- The United States holds the largest market share of Crohn’s Disease among the 7MM countries. In 2021, the market size of Crohn’s Disease in the US was USD 6,174 million.
- In 2021, among the EU-5 countries, Germany had the highest market share, followed by UK and Italy.
- Spain holds the smallest share of the 7MM Crohn’s Disease market with a market size of USD 167 million in 2021 that is expected to increase by 2032.
The United States Market Outlook
This section provides the total Crohn’s Disease market size and market size by therapies in the United States.
EU-5 Market Outlook
The total Crohn’s Disease market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.
Japan Market Outlook
The total Crohn’s Disease market size and market size by therapies in Japan are provided.
Crohn’s Disease Drugs Uptake
This section focuses on the rate of uptake of the potential drugs recently launched in the Crohn’s Disease market or expected to get launched in the market during the study period 2019–2032. The analysis covers the Crohn’s Disease market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Crohn’s Disease Development Activities
The report provides insights into different therapeutic candidates in Phase II and Phase III stage. It also analyzes key players involved in developing targeted therapeutics.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Crohn’s Disease emerging therapies.
Reimbursement Scenario in Crohn’s Disease
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
Competitive Intelligence Analysis
We perform competitive market Intelligence analysis of the Crohn’s Disease market by using various competitive intelligence tools that include–SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
Scope of the Report
- The report covers the descriptive overview of Crohn’s Disease, explaining its causes, symptoms, pathophysiology, genetic basis, diagnosis, and currently available therapies.
- Comprehensive insight has been provided into the Crohn’s Disease epidemiology and treatment.
- Additionally, an all-inclusive account of both the current and emerging therapies for Crohn’s Disease is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
- A detailed review of the Crohn’s Disease market; historical and forecasted is included in the report, covering the 7MM drug outreach.
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Crohn’s Disease market.
Report Highlights
- The robust pipeline with novel MOA and oral ROA, increasing prevalence, and effectiveness of drugs will positively drive the Crohn’s Disease market.
- The companies and academics are working to assess challenges and seek opportunities that could influence Crohn’s Disease R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
- Major players are involved in developing therapies for Crohn’s Disease. The launch of emerging therapies will significantly impact the Crohn’s Disease market.
- Our in-depth analysis of the pipeline assets across different stages of development (phase III and phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
Crohn’s Disease Report Insights
- Patient Population
- Therapeutic Approaches
- Crohn’s Disease Pipeline Analysis
- Crohn’s Disease Market Size and Trends
- Market Opportunities
- Impact of upcoming Therapies
Crohn’s Disease Report Key Strengths
- 11 Years Forecast
- 7MM Coverage
- Crohn’s Disease Epidemiology Segmentation
- Key Cross Competition
- Highly Analyzed Market
- Drugs Uptake
Crohn’s Disease Report Assessment
- Current Treatment Practices
- Unmet Needs
- Pipeline Product Profiles
- Market Attractiveness
- Market Drivers and Barriers
- SWOT analysis
Key Questions
Market Insights:
- What was Crohn’s Disease market share (%) distribution in 2019 and how it would look like in 2032?
- What would be the Crohn’s Disease total market size as well as market size by therapies across the 7MM during the forecast period (2022–2032)?
- What are the key findings pertaining to the market across the 7MM and which country will have the largest Crohn’s Disease market size during the forecast period (2022–2032)?
- At what CAGR, the Crohn’s Disease market is expected to grow at the 7MM level during the forecast period (2022–2032)?
- What would be the Crohn’s Disease market outlook across the 7MM during the forecast period (2022–2032)?
- What would be the Crohn’s Disease market growth till 2032 and what will be the resultant market size in the year 2032?
- How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
Epidemiology Insights:
- What are the disease risk, burdens, and unmet needs of Crohn’s Disease?
- What is the historical Crohn’s Disease patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
- What would be the forecasted patient pool of Crohn’s Disease at the 7MM level?
- What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Crohn’s Disease?
- Out of the above-mentioned countries, which country would have the highest population of Crohn’s Disease during the forecast period (2022–2032)?
- At what CAGR the population is expected to grow across the 7MM during the forecast period (2022–2032)?
Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:
- What are the current options for the treatment of Crohn’s Disease along with the approved therapy?
- What are the current treatment guidelines for the treatment of Crohn’s Disease?
- What are the Crohn’s Disease marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
- How many companies are developing therapies for the treatment of Crohn’s Disease?
- How many emerging therapies are in the mid-stage and late stages of development for the treatment of Crohn’s Disease?
- What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Crohn’s Disease therapies?
- What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Crohn’s Disease and their status?
- What are the key designations that have been granted for the emerging therapies for Crohn’s Disease?
- What are the 7MM historical and forecasted market of Crohn’s Disease?
Reasons to buy
- The report will help in developing business strategies by understanding trends shaping and driving Crohn’s Disease.
- To understand the future market competition in the Crohn’s Disease market and an insightful review of the key market drivers and barriers.
- Organize sales and marketing efforts by identifying the best opportunities for Crohn’s Disease in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
- Organize sales and marketing efforts by identifying the best opportunities for the Crohn’s Disease market.
- To understand the future market competition in the Crohn’s Disease market.
1. Key Insights
2. Report Introduction
3. Crohn’s Disease (CD) Market Overview at a Glance
3.1. Market Share (%) Distribution of Crohn’s Disease (CD) by class in 2019
3.2. Market Share (%) Distribution of Crohn’s Disease (CD) by class in 2032
4. Crohn’s Disease (CD) Market: Future Prospects
5. Executive Summary of Crohn’s Disease (CD)
6. Key Events
7. Crohn’s Disease (CD): Disease Background and Overview
7.1. Introduction
7.2. Types of CD
7.3. Classification of CD
7.4. Signs and Symptoms of CD
7.5. Risk Factors and Causes of CD
7.6. Pathophysiology of CD
7.7. Complications of CD
7.8. Diagnosis of CD
7.8.1. Diagnostic Algorithm
7.8.2. Physical Exam
7.8.3. Diagnostic Tests
7.8.4. Imaging Tests
7.8.5. Differential Diagnosis
7.8.6. Antibody blood tests (Biomarkers)
7.8.7. Diagnostic Guidelines of CD
7.9. Treatment and Management of Crohn’s Disease
7.9.1. Treatment Algorithm of CD
7.9.2. Drug Therapies
7.9.3. Other therapies
7.9.4. Surgery
7.9.5. Diet and Nutrition
7.10. Treatment and Management Guidelines of CD
7.10.1. American College of Gastroenterology (ACG) guidelines
7.10.2. American Gastroenterological Association Institute Guideline on the Management of CD after Surgical Resection
7.10.3. ECCO Guidelines on Therapeutics in Crohn’s Disease: Medical Treatment
7.10.4. Therapeutic Algorithm of CD in Japan
7.10.5. Therapeutic Options for IBD in Japan, Europe and US
8. Epidemiology and Patient Population
8.1. Key Findings
8.2. Epidemiology Methodology
8.3. Assumptions and Rationales: 7MM
8.4. Total Prevalent Cases of Crohn’s Disease in the 7MM
8.5. Total Diagnosed Prevalent Cases of Crohn’s Disease in the 7MM
8.6. United States
8.6.1. Total Prevalent Cases of Crohn’s Disease in the United States
8.6.2. Total Diagnosed Prevalent Cases of Crohn’s Disease in the United States
8.6.3. Age-specific Diagnosed Prevalent Cases of Crohn’s Disease in the United States
8.6.4. Severity-specific Diagnosed Prevalent Cases of Crohn’s Disease in the United States
8.7. Europe
8.7.1. Total Prevalent Cases of Crohn’s Disease in EU-5
8.7.2. Total Diagnosed Prevalent Cases of Crohn’s Disease in the EU-5
8.7.3. Age-specific Diagnosed Prevalent Cases of Crohn’s Disease in the EU-5
8.7.4. Severity-specific Diagnosed Prevalent Cases of Crohn’s Disease in the EU-5
8.8. Japan
8.8.1. Total Prevalent Cases of Crohn’s Disease in Japan
8.8.2. Total Diagnosed Prevalent Cases of Crohn’s Disease in Japan
8.8.3. Age-specific Diagnosed Prevalent Cases of Crohn’s Disease in Japan
8.8.4. Severity-specific Diagnosed Prevalent Cases of Crohn’s Disease in Japan
9. Patient Journey
10. Marketed Products
10.1. Key-cross Competition
10.2. Entyvio (Vedolizumab): Takeda Pharmaceutical
10.2.1. Product Description
10.2.2. Regulatory Milestones
10.2.3. Other Developmental Activity
10.2.4. Pivotal Clinical Trial
10.2.5. Clinical Trials Information
10.2.6. Product Profile
10.3. Stelara (Ustekinumab): Janssen Pharmaceuticals
10.3.1. Product Description
10.3.2. Regulatory Milestones
10.3.3. Other Developmental Activities
10.3.4. Pivotal Clinical Trial
10.3.5. Clinical Trials Information
10.3.6. Product Profile
10.4. Cimzia (Certolizumab-pegol): UCB
10.4.1. Product Description
10.4.2. Regulatory Milestones
10.4.3. Other Developmental Activities
10.4.4. Pivotal Clinical Trial
10.4.5. Clinical Trials Information
10.4.6. Product Profile
10.5. Tysabri (Natalizumab): Biogen
10.5.1. Product Description
10.5.2. Regulatory Milestones
10.5.3. Other Developmental Activities
10.5.4. Pivotal Clinical Trial
10.5.5. Clinical Trials Information
10.5.6. Product Profile
10.6. Remicade (Infliximab): Janssen Biotech
10.6.1. Product Description
10.6.2. Regulatory Milestones
10.6.3. Other Developmental Activities
10.6.4. Pivotal Clinical Trial
10.6.5. Clinical Trials Information
10.6.6. Product Profile
10.7. Humira (Adalimumab): AbbVie
10.7.1. Product Description
10.7.2. Regulatory Milestones
10.7.3. Other Developmental Activities
10.7.4. Pivotal Clinical Trial
10.7.5. Clinical Trials Information
10.7.6. Product Profile
10.8. Alofisel (Darvadstrocel/Cx601): Takeda Pharmaceuticals
10.8.1. Product Description
10.8.2. Regulatory Milestones
10.8.3. Other Developmental activities
10.8.4. Pivotal Clinical Trial
10.8.5. Clinical Trials Information
10.8.6. Product Profile
10.9. Budesonide (Entocort/Zentacort)/ Budesonide-Multi-Matrix System (MMX): AstraZeneca/Tillotts Pharma (Zeria Pharmaceutical)
10.9.1. Drug Description
10.9.2. Regulatory Milestone
10.9.3. Other Developmental Activities
10.9.4. Clinical Development
10.9.5. Clinical Trials Information
10.9.6. Safety and Efficacy
10.9.7. Product Profile
11. Emerging Therapies
11.1. Key Cross Competition
11.2. Jyselica (Filgotinib/GS-6034): Gilead Sciences and Galapagos NV
11.2.1. Product Description
11.2.2. Other Developmental Activities
11.2.3. Clinical Development
11.2.4. Safety and Efficacy
11.2.5. Product Profile
11.3. Skyrizi (Risankizumab, ABBV-066, BI 655066): AbbVie and Boehringer Ingelheim
11.3.1. Product Description
11.3.2. Other Developmental Activities
11.3.3. Clinical Development
11.3.4. Clinical Trials Information
11.3.5. Safety and Efficacy
11.3.6. Product Profile
11.4. Mirikizumab (LY3074828): Eli Lilly and Company
11.4.1. Product Description
11.4.2. Clinical Development
11.4.3. Safety and Efficacy
11.4.4. Product Profile
11.5. RHB-104: RedHill Biopharma
11.5.1. Product Description
11.5.2. Other Developmental Activities
11.5.3. Clinical Development
11.5.4. Safety and Efficacy
11.5.5. Product Profile
11.6. Rinvoq (Upadacitinib; ABT494): AbbVie
11.6.1. Product Description
11.6.2. Other Developmental Activities
11.6.3. Clinical Development
11.6.4. Safety and Efficacy
11.6.5. Product Profile
11.7. Zeposia (Ozanimod; RPC1063): Celgene (Bristol Myers Squibb)
11.7.1. Product Description
11.7.2. Other Developmental Activities
11.7.3. Clinical Development
11.7.4. Clinical Trials Information
11.7.5. Safety and Efficacy
11.7.6. Product Profile
11.8. Brazikumab (MEDI 2070): AstraZeneca
11.8.1. Product Description
11.8.2. Regulatory Milestones
11.8.3. Other Developmental Activities
11.8.4. Clinical Development
11.8.5. Clinical Trials Information
11.8.6. Safety and Efficacy
11.8.7. Product Profile
11.9. Etrasimod (APD334): Arena Pharmaceuticals
11.9.1. Product Description
11.9.2. Other Developmental Activities
11.9.3. Clinical Development
11.9.4. Clinical Trials Information
11.9.5. Product Profile
11.10. Tremfya (Guselkumab): Janssen (Johnson and Johnson)
11.10.1. Drug Description
11.10.2. Other Developmental Activities
11.10.3. Clinical Development
11.10.4. Clinical Trials Information
11.10.5. Safety and Efficacy
11.10.6. Product Profile
11.11. Ryoncil (Remestemcel-l): Mesoblast
11.11.1. Drug Description
11.11.2. Other Developmental Activities
11.11.3. Clinical Development
11.11.4. Clinical Trials Information
11.11.5. Safety and Efficacy
11.11.6. Product Profile
12. Crohn’s Disease (CD): Seven Major Market Analysis
12.1. Key Findings
12.2. Market Methodology
12.3. Market Size of Crohn’s Disease (CD) in the 7MM
12.4. Market Size of Crohn’s Disease (CD) by Therapies in the 7MM
13. Attribute Analysis
14. Potential of Emerging Therapies
15. Key Market Forecast Assumptions
16. Market Outlook
16.1. United States Market Size
16.1.1. Total Market Size of Crohn’s Disease in the United States
16.1.2. Market Size of Crohn’s Disease by Therapies in the United States
16.2. EU-5 Market Size
16.2.1. Total Market Size of Crohn’s Disease in EU-5
16.2.2. Market Size of Crohn’s Disease by Therapies in EU-5
16.3. Japan
16.3.1. Total Market size of Crohn’s Disease in Japan
16.3.2. Market Size of Crohn’s Disease by Therapies in Japan
17. Market Drivers
18. Market Barriers
19. SWOT Analysis
20. Unmet Needs
21. KOL Views
22. Reimbursement and Market access
22.1. United States
22.2. Europe
22.3. Japan
23. Appendix
23.1. Bibliography
23.2. Report Methodology
24. DelveInsight Capabilities
25. Disclaimer
26. About DelveInsight
List of Table
Table 1: Summary of Crohn’s Disease Market and Epidemiology (2019–2032)
Table 2: Key Events
Table 3: Difference between Crohn’s Disease and Ulcerative Colitis
Table 4: Vienna and Montreal classification for CD
Table 5: Genes with functions associated with CD
Table 6: Cytokines associated with CD
Table 7: ECCO-ESGAR Diagnostics guidelines
Table 8: ECCO Guidelines on Therapeutics in CD
Table 9: Total Prevalent Cases of Crohn’s Disease in the 7MM (2019−2032)
Table 10: Total Prevalent Cases of Crohn’s Disease in the United States (2019−2032)
Table 11: Total Prevalent Cases of Crohn’s Disease in the United States (2019−2032)
Table 12: Total Diagnosed Prevalent Cases of Crohn’s Disease in the United States (2019-2032)
Table 13: Age-specific Diagnosed Prevalent Cases of Crohn’s Disease in the United States (2019-2032)
Table 14: Age-specific Diagnosed Prevalent Cases of Crohn’s Disease in the United States (2019-2032)
Table 15: Total Prevalent Cases of Crohn’s Disease in the EU-5 (2019−2032)
Table 16: Total Diagnosed Prevalent Cases of Crohn’s Disease in the EU-5 (2019−2032)
Table 17: Age-specific Diagnosed Prevalent Cases of Crohn’s Disease in the EU-5 (2019-2032)
Table 18: Severity-specific Diagnosed Prevalent Cases of Crohn’s Disease in the EU-5 (2019-2032)
Table 19: Total Prevalent Cases of Crohn’s Disease in Japan (2019−2032)
Table 20: Total Diagnosed Prevalent Cases of Crohn’s Disease in Japan (2019-2032)
Table 21: Age-specific Diagnosed Prevalent Cases of Crohn’s Disease in Japan (2019-2032)
Table 22: Severity-specific Diagnosed Prevalent Cases of Crohn’s Disease in Japan (2019-2032)
Table 23: Key cross competition- Marketed drugs
Table 24: Entyvio (Vedolizumab), Summary of Pivotal Trial
Table 25: Entyvio (Vedolizumab), Clinical Trial Description, 2022
Table 26: Stelara (Ustekinumab), Summary of Pivotal Trial
Table 27: Stelara (Ustekinumab), Clinical Trial Description, 2022
Table 28: Cimzia (Certolizumab-pegol), Summary of Pivotal Trial
Table 29: Stelara (Ustekinumab), Clinical Trial Description, 2022
Table 30: Tysabri (natalizumab), Summary of Pivotal Trial
Table 31: Tysabri (Natalizumab), Clinical Trial Description, 2022
Table 32: Remicade (Infliximab), Summary of Pivotal Trial
Table 33: Remicade (Infliximab), Clinical Trial Description, 2022
Table 34: Humira (Adalimumab), Summary of Pivotal Trial
Table 35: Humira (Adalimumab), Clinical Trial Description, 2022
Table 36: Alofisel (Darvadstrocel), Clinical Trial Description, 2022
Table 37: Budesonide (Entocort/Zentacort), Clinical Trial Description, 2022
Table 38: Key cross competition- Emerging Therapies
Table 39: Jyselica (Filgotinib/ GS-) Clinical Trial Description, 2022
Table 40: Risankizumab-Clinical Trial Description, 2022
Table 41: Mirikizumab -Clinical Trial Description, 2022
Table 42: RHB-104 -Clinical Trial Description, 2022
Table 43: Upadacitnib-Clinical Trial Description, 2022
Table 44: Zeposia (Ozanimod; RPC1063), Clinical Trial Description, 2022
Table 45: Brazikumab (MEDI-2070), Clinical Trial Description, 2022
Table 46: Etrasimod, Clinical Trial Description, 2022
Table 47: Tremfya (Guselkumab), Clinical Trial Description, 2022
Table 48: Ryoncil (Remestemcel), Clinical Trial Description, 2022
Table 49: Market Size of Crohn’s Disease (CD) in the 7MM in USD Million (2019–2032)
Table 50: Market Size of Crohn’s Disease (CD) in the 7MM in USD Million (2019–2032)
Table 51: Key Market Forecast Assumptions for Zeposia
Table 52: Key Market Forecast Assumptions for Risankizumab
Table 53: Key Market Forecast Assumptions for Brazikumab
Table 54: Key Market Forecast Assumptions for Alofisel
Table 55: Key Market Forecast Assumptions for Mirikizumab
Table 56: Key Market Forecast Assumptions for RHB-104
Table 57: Key Market Forecast Assumptions for Etrasimod
Table 58: Key Market Forecast Assumptions for Tremfya
Table 59: United States Market Size of Crohn’s Disease in USD Million (2019–2032)
Table 60: United States Market Size of Crohn’s Disease by Therapies in USD Million (2019–2032)
Table 61: EU-5 Market Size of Crohn’s Disease in USD Million (2019–2032)
Table 62: EU-5 Market Size of Crohn’s Disease by Therapies in USD Million (2019–2032)
Table 63: Japan Market Size of Crohn’s Disease in USD Million (2019–2032)
Table 64: Japan Market Size of Crohn’s Disease by Therapies in USD Million (2019–2032)
List of Figures
Figure 1: Inflammatory Bowel Disease Subsets
Figure 2: Difference between CD And Ulcerative Colitis
Figure 3: Types OF CD
Figure 4: Signs and Symptoms
Figure 5: Causes and Risk Factors of CD
Figure 6: Immuno-Mediated Pathogenesis of CD
Figure 7: Local Complications of CD
Figure 8: Systemic Complications of CD
Figure 9: Diagnostic Algorithm
Figure 10: Capsule Endoscopy
Figure 11: CT Scan
Figure 12: Diagnostic Guideline Algorithm for CD
Figure 13: Treatment Algorithm of CD
Figure 14: Therapeutic Algorithm of CD in JAPAN
Figure 15: Total Prevalent Cases of Crohn’s Disease in the 7MM (2019-2032)
Figure 16: Total Diagnosed Prevalent Cases of Crohn’s Disease in the 7MM (2019-2032)
Figure 17: Total Prevalent Cases of Crohn’s Disease in the United States (2019-2032)
Figure 18: Total Diagnosed Prevalent Cases of Crohn’s Disease in the United States (2019-2032)
Figure 19: Age-Specific Diagnosed Prevalent Cases of Crohn’s Disease in the United States (2019-2032)
Figure 20: Severity-Specific Diagnosed Prevalent Cases of Crohn’s Disease in the United States (2019-2032)
Figure 21: Total Prevalent Cases of Crohn’s Disease in the EU-5 (2019-2032)
Figure 22: Total Diagnosed Prevalent Cases of Crohn’s Disease in the EU-5 (2019-2032)
Figure 23: Age-Specific Diagnosed Prevalent Cases of Crohn’s Disease in the EU-5 (2019-2032)
Figure 24: Severity-Specific Diagnosed Prevalent Cases of Crohn’s Disease in the EU-5 (2019-2032)
Figure 25: Total Prevalent Cases of Crohn’s Disease in Japan (2019-2032)
Figure 26: Total Diagnosed Prevalent Cases of Crohn’s Disease in Japan (2019-2032)
Figure 27: Age-Specific Diagnosed Prevalent Cases of Crohn’s Disease in Japan (2019-2032)
Figure 28: Severity-Specific Diagnosed Prevalent Cases of Crohn’s Disease in Japan (2019-2032)
Figure 29: Market Size of Crohn’s Disease (CD) in the 7MM in USD million (2019–2032)
Figure 30: Seven Major Market Size of Crohn’s Disease (CD) By Therapies in the 7MM, In USD million (2019–2032)
Figure 31: Market Size of Crohn’s Disease in the United States, USD million (2019–2032)
Figure 32: The United States Market Size of Crohn’s Disease by therapies in USD million (2019–2032)
Figure 33: Market Size of Crohn’s Disease in the EU-5, USD million (2019–2032)
Figure 34: EU-5 Market Size of Crohn’s Disease by therapies in USD million (2019–2032)
Figure 35: Market Size of Crohn’s Disease in Japan, USD million (2019–2032)
Figure 36: Japan Market Size of Crohn’s Disease by therapies in USD million (2019–2032)
Figure 37: Market Drivers
Figure 38: Market Barriers
Figure 39: Unmet Needs
Takeda Pharmaceutical
Janssen Pharmaceuticals
UCB
Biogen
AbbVie
AstraZeneca
Tillotts Pharma (Zeria Pharmaceutical)
Gilead Sciences and Galapagos NV
Boehringer Ingelheim
Celgene (Bristol Myers Squibb)
Eli Lilly and Company
RedHill Biopharma
Arena Pharmaceuticals
Mesoblast